To prescribe controlled substances legally in New Hampshire, you need an active state professional license, a Controlled Substance Registration from the New Hampshire Board of Pharmacy, and a federal DEA registration, and you must follow the state’s rules on electronic prescribing, opioid limits, Prescription Drug Monitoring Program checks, and record-keeping. New Hampshire controlled substance prescribing laws pull from state statute (RSA 318-B), Board of Medicine administrative rules, and federal DEA requirements, and every prescriber has to satisfy all three layers.
The Three Credentials You Need First
Prescribing authority in New Hampshire is built from three separate credentials stacked together. Missing any one of them makes prescribing illegal regardless of the others.
The first is a professional license. Physicians, nurse practitioners, physician assistants, dentists, and podiatrists must hold an active license through their respective regulatory board, such as the Board of Medicine or the Board of Nursing.
The second is a state Controlled Substance Registration (CSR) issued by the New Hampshire Board of Pharmacy. The CSR authorizes prescribing, administering, or dispensing controlled drugs within the state and must be renewed every two years.
The third is a federal DEA registration. A DEA registration is tied to a specific physical practice location, so a provider who practices at multiple offices needs a separate registration for each one.1Drug Enforcement Administration. Registration Q&A DEA registrations renew every three years.
Training and Continuing Education
Two separate education requirements attach to those credentials. The federal Medication Access and Training Expansion (MATE) Act, effective June 2023, requires DEA-registered practitioners (other than veterinarians) to complete at least eight hours of one-time training on treating and managing patients with opioid or other substance use disorders before their DEA registration will be issued or renewed.2Drug Enforcement Administration. Opioid Use Disorder – MATE Act Q&A It’s a one-time attestation, and prior DATA-Waiver training hours count toward it.
On top of the federal requirement, RSA 318-B:40 requires every prescriber holding a DEA registration to complete three contact hours of board-approved continuing education in pain management, addiction disorders, or a combination, as a condition of both initial licensure and each renewal.3New Hampshire General Court. New Hampshire Revised Statutes Chapter 318-B Section 318-B:40 – Competency Requirements The training is offered at no cost through an approved online program or examination.
Electronic Prescribing Is the Default
Under RSA 318:47-c, controlled substance prescriptions in New Hampshire must be transmitted electronically rather than on paper.4New Hampshire General Court. New Hampshire Revised Statutes Section 318:47-c The statute recognizes a limited set of exceptions:
- Temporary technology or electrical failure that makes e-prescribing unavailable.
- Prescriptions that will be filled by a pharmacy located outside New Hampshire.
- Prescriptions issued by a prescriber who is also dispensing the medication.
- Prescriptions for FDA-restricted drugs where required prescription elements can’t be accommodated electronically.
- A waiver granted by the prescriber’s licensing board, which cannot exceed one year.
The e-prescribing platform itself has to meet federal security standards, including two-factor authentication for signing prescriptions and an audit trail. Any alteration to a signed prescription automatically cancels it.5eCFR. Requirements for Electronic Orders and Prescriptions
What the Prescription Must Contain
Whether electronic or issued under an exception, every controlled substance prescription must include the patient’s full name and address, the name and strength of the drug, specific directions for use, the prescriber’s DEA registration number, and the prescriber’s signature dated the day of issuance. Only one controlled drug may appear per prescription blank, and Schedule II prescriptions cannot include refills.6New Hampshire General Court. New Hampshire Revised Statutes Section 318-B:9 – Sale by Pharmacists
Opioid Prescribing for Acute Pain
Board of Medicine rule Med 502.04 governs opioid prescribing for acute pain. Before prescribing, the provider must conduct and document a physical examination and patient history, assess the patient’s risk for misuse or diversion, and prescribe the lowest effective dose for a limited duration.7Legal Information Institute. New Hampshire Code of Administrative Rules Section Med 502.04 – Acute Pain The prescriber is also expected to discuss the risks of addiction and consider non-opioid alternatives, and those conversations should appear in the record.
RSA 318-B:41 directs regulatory boards to set specific day-supply limits for opioid prescriptions issued in emergency departments, urgent care settings, and walk-in clinics.8New Hampshire General Court. New Hampshire Revised Statutes Section 318-B:41 If acute pain persists beyond 30 days and continued opioid therapy is indicated, the prescriber must conduct an in-office follow-up before issuing a new prescription. That reassessment requirement is the state’s built-in checkpoint before acute treatment slides into chronic use.
Long-Term Opioid Therapy
When opioid treatment moves into chronic pain management, RSA 318-B:41 requires a written treatment agreement between provider and patient that lays out the responsibilities of each.8New Hampshire General Court. New Hampshire Revised Statutes Section 318-B:41 Board of Medicine rules then require the prescriber to reevaluate the treatment plan and the continued use of opioids at least twice per year, assessing benefit, signs of dependency, and whether non-opioid options might work better.
New Hampshire’s rules don’t set a hard dosage ceiling, but the CDC’s clinical practice guideline urges careful reassessment once a patient’s total opioid dosage reaches 50 morphine milligram equivalents (MME) per day, citing observational data showing a roughly two-to-fivefold increase in overdose risk at 50 to under 100 MME per day compared to under 20 MME, and up to nine times the risk at 100 MME or above.9Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022 At 50 MME per day or above, the CDC recommends more frequent follow-ups and co-prescribing naloxone with overdose prevention education for the patient and household.
Checking the Prescription Drug Monitoring Program
New Hampshire’s Prescription Drug Monitoring Program, established under RSA 318-B:31 through 318-B:40, tracks every Schedule II through IV controlled substance dispensed in the state. Prescribers must register with the program, query it before prescribing initial Schedule II, III, or IV opioids for pain, and check it at least twice a year for patients on ongoing therapy.10Legal Information Institute. New Hampshire Admin Code Med 502.06 – Prescription Drug Monitoring Program
The rules allow you to skip the PDMP check in three situations: when the medication is being administered directly to a patient in a healthcare setting, when the PDMP system is down due to a technical failure, and when an emergency department is experiencing patient volume high enough that querying would materially delay care. Outside those, failing to check is a compliance violation, and it’s one regulators can catch easily because the PDMP logs every query.
Records and Inventory
RSA 318-B:12 requires prescribers to maintain records of every controlled substance they prescribe, administer, or dispense, including the drug’s name, dosage form, strength, and quantity, along with the name and address of the patient and the date of the transaction.11New Hampshire General Court. New Hampshire Revised Statutes Section 318-B:12 – Records to be Kept; Confidentiality Records must be available for inspection by regulatory authorities.
The clinical record should go further: patient evaluations, treatment plans, risk assessments, discussions about addiction, alternatives considered, and any written pain management agreement. Boards tend to be far more lenient with providers whose files show they followed the process than with those whose records have gaps.
Providers who keep controlled substances on-site must also comply with federal inventory rules. DEA regulations require a complete physical inventory of all controlled substances on hand at least every two years, noting whether it was taken at the opening or close of business.12eCFR. Inventory Requirements Schedule I and II substances require an exact count. Schedules III through V allow an estimated count unless the container holds more than 1,000 tablets or capsules, in which case an exact count is required. The inventory must be kept in written, typewritten, or printed form at the registered location.
Telehealth Prescribing
The federal Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires at least one in-person evaluation before a provider can prescribe controlled substances remotely. Pandemic-era flexibilities suspending that requirement have been extended through December 31, 2026.13Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
Under the current extension, a DEA-registered practitioner may prescribe Schedule II through V controlled substances via telemedicine without a prior in-person evaluation, provided the prescription is issued for a legitimate medical purpose in the usual course of professional practice, the consultation uses an approved interactive telecommunications system, and the prescription otherwise complies with all standard DEA requirements. Once you’ve conducted at least one in-person evaluation with a patient, the Ryan Haight restrictions no longer apply to that relationship. If the flexibility expires without replacement at the end of 2026, remote controlled substance prescribing for new patients would again require a prior in-person visit.
Disposing of Controlled Substances
Controlled substances a practitioner no longer needs can’t be discarded in the trash. Federal regulations recognize four disposal paths:14eCFR. Part 1317 – Disposal
- On-site destruction witnessed by two employees, with the substance rendered completely non-retrievable.
- Transfer to a registered reverse distributor.
- Return to the registered manufacturer or an authorized return agent.
- Submission of DEA Form 41 to the local Special Agent in Charge for instructions.
Hospitals and clinics with on-site pharmacies may also apply to become authorized collectors and maintain secure take-back receptacles. Every return or recall must be documented, and any transfer of Schedule I or II substances requires a DEA order form.
Penalties for Violations
Under RSA 318-B:26, criminal penalties are in addition to, not instead of, any civil or administrative sanctions.15New Hampshire General Court. New Hampshire Revised Statutes Section 318-B:26 – Penalties A single incident can produce a criminal charge, a board disciplinary action, and a malpractice suit.
On the criminal side, unlawful distribution of a Schedule I or II narcotic substance in a quantity under one ounce carries a maximum of seven years in prison and a fine up to $100,000 for a first offense, rising to 15 years and up to $200,000 for a second or subsequent offense. The DEA may run its own investigation in parallel, particularly where interstate activity or fraudulent prescribing is suspected.
Administrative consequences can end a career. Board actions range from mandatory education to temporary suspension to permanent revocation of prescribing privileges. Lower-level issues, such as inadequate documentation, missed PDMP checks, or prescribing without a current CSR, are often what draws the initial investigation. Consistent documentation and monitoring compliance are the most reliable protection.